Glenmark Pharmaceuticals Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Net profit of Glenmark Pharmaceuticals rose 15.88% to Rs 403.21 crore in the quarter ended December 2025 as against Rs 347.96 crore during the previous quarter ended December 2024. Sales rose 17.75% to Rs 3888.00 crore in the quarter ended December 2025 as against Rs 3301.90 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 30 January 2026.

Powered by Capital Market - Live News

The company said that its Epinephrine Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) manufactured by BPI Labs, LLC (NDA 205029).

Epinephrine Injection is commonly used in emergency medical settings for the treatment of severe allergic reactions and other critical conditions.

According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market recorded annual sales of approximately $67.6 million, indicating a sizeable opportunity in the US generics market.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, ?We are excited to announce the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.?

Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets.

Glenmark Pharmaceuticals, the company, reported a 72.3% jump in consolidated net profit to Rs 610.25 crore on a 76.6% increase in revenue from operations to Rs 6,003.79 crore in Q2 FY25.

Shares of Glenmark Pharmaceuticals rose 0.20% to Rs 2,042.70 on the BSE.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial. Glenmark's Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) of BPI Labs, LLC, NDA 205029.

Powered by Capital Market - Live News